05:04 AM EDT, 08/19/2026 (MT Newswires) -- Biovica International (BIOVIC-B.ST) secured a contract worth $287,000 to deliver its DiviTum TKa testing assay services to an existing undisclosed client. The customer will use the Swedish biotechnology group's pharma services for its early-stage clinical development breast cancer treatment trial that will evaluate a CDK2/4 inhibitor field. The company noted that it will start sample testing between January 2027 and February 2027 at its CLIA-certified laboratory in California, US.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.